Attenuated recombinant newcastle disease virus and vaccine containing the same
US8173136B2 · kind B2 · utility
1Cited by
4References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 27, 2006 |
| Grant date | May 8, 2012 |
| Priority date | — |
| Expiry date | Jan 17, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18162
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a recombinant vector for transcription of the Newcastle disease virus (NDV) genome, a strain of attenuated recombinant NDV with a surface antigen of pathogenic NDV prepared by the vector, a method of preparing a recombinant NDV having low pathogenicity and high protectivity efficiency against Newcastle disease (ND) using the vector, and a vaccine against ND containing the recombinant NDV.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.